CD105 (Endoglin / TGF-Beta1/3 Receptor) antibody (PE)

Details for Product No. ABIN302200
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms CD105, AI528660, AI662476, S-endoglin, END, HHT1, ORW1
Reactivity
Human, Pig (Porcine)
(224), (94), (35), (33), (25), (13), (13), (6), (1)
Host
Mouse
(142), (118), (40), (2), (2)
Clonality (Clone)
Monoclonal ()
Conjugate
PE
(30), (26), (19), (9), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1)
Application
Flow Cytometry (FACS)
(187), (163), (64), (57), (46), (42), (38), (29), (22), (15), (7), (7), (5), (4), (4), (1), (1)
Pubmed 5 references available
Catalog no. ABIN302200
Quantity 100 tests
Price
412.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Recombinant Vaccinia virus containing the Human CD105 (L-isoform) cDNA
Clone MEM-229
Isotype IgG2a
Characteristics Synonyms: ENG, END, HHT1, ORW, ORW1
Purification Size-Exclusion Chromatography
Alternative Name CD105 / Endoglin
Background CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence ofTGFbR-2 as a receptor for TGFb-1 and TGFb-3. CD105 is highly expressed on endothelialcells and promotes angiogenesis during wound healing, infarcts and in a wide range oftumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis inhypoxic endothelial cells and also antagonises the inhibitory effects of TGFb-1 on vascularendothelial cell growth and migration. Normal cellular levels of CD105 are required forformation of new blood vessels.
UniProt P17813
Research Area CD Antigens, Surface Receptors of Immune Cells
Application Notes Flow Cytometry analysis of Human blood cells using 20 µl reagent/100 µl of whole blood or10e6 cells in a suspension. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer Phosphate buffered saline (PBS) containing 15 mM Sodium Azide and 0.2% (w/v) high-grade protease free BSA as a stabilizing agent.
Preservative Sodium azide
Storage 4 °C
Storage Comment Store the antibody at 2-8°C. DO NOT FREEZE! This product is photosensitive and should be protected from light. Shelf life: one year from despatch.
Expiry Date 12 months
Supplier Images
anti-CD105 (Endoglin / TGF-Beta1/3 Receptor) antibody (PE) anti-CD105 (Endoglin / TGF-Beta1/3 Receptor) antibody (PE)
Background publications Li, Issa, Kumar et al.: "CD105 prevents apoptosis in hypoxic endothelial cells." in: Journal of cell science, Vol. 116, Issue Pt 13, pp. 2677-85, 2003 (PubMed).

Zhu, Sun, Xie et al.: "Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells." in: Stroke; a journal of cerebral circulation, Vol. 34, Issue 10, pp. 2483-8, 2003 (PubMed).

Guo, Slevin, Li et al.: "CD105 inhibits transforming growth factor-beta-Smad3 signalling." in: Anticancer research, Vol. 24, Issue 3a, pp. 1337-45, 2004 (PubMed).

Warrington, Hillarby, Li et al.: "Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells." in: Anticancer research, Vol. 25, Issue 3B, pp. 1851-64, 2005 (PubMed).

Piao, Tokunaga: "Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study." in: Journal of atherosclerosis and thrombosis, Vol. 13, Issue 2, pp. 82-9, 2006 (PubMed).

Hosts (142), (118), (40), (2), (2)
Reactivities (224), (94), (35), (33), (25), (13), (13), (6), (1)
Applications (187), (163), (64), (57), (46), (42), (38), (29), (22), (15), (7), (7), (5), (4), (4), (1), (1)
Conjugates (30), (26), (19), (9), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1)
Epitopes (9), (5), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
back to top